WO2002017944A1 - Use of a composition comprising an extract of pollen for the treatment of hormonally-related disorders - Google Patents
Use of a composition comprising an extract of pollen for the treatment of hormonally-related disorders Download PDFInfo
- Publication number
- WO2002017944A1 WO2002017944A1 PCT/SE2001/001851 SE0101851W WO0217944A1 WO 2002017944 A1 WO2002017944 A1 WO 2002017944A1 SE 0101851 W SE0101851 W SE 0101851W WO 0217944 A1 WO0217944 A1 WO 0217944A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pollen
- extract
- optionally
- vitamin
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the invention relates in a first aspect to a method for the treatment of disorders related to normal hormonal change in women in peri- and post-menopausal age, by the administering of a composition comprising, as active ingredients, a water- and/or fat-soluble cytosolic extract of pollen and optionally pistils.
- the invention in another aspect, relates to the use of a composition comprising, as active ingredients, a water- and/or fat-soluble cytosolic extract of pollen and optionally pistils for the manufacturing of a medicament for the treatment of disorders relating to normal hormonal change in women in peri- and post-menopausal age.
- Menopause which is caused by a lowering of the production of female sex hormones at the age around 50, can to many women generate disorders such as hot flushes, attacks of sweating, muscle and possibly joint pain, sleep disturbances, dysphoria, nervousness, mood swings, headache, palpitations (enhanced frequency of heart rate), dry mucous membranes and pain during intercourse, urinary disturbances such as stress incontinence, frequent passing water and pain /irritability of the bladder and urethra during the process of passing water etc. All these disorders reflect age related hormonal changes which hitherto only have been alleviated effectively by the administration of female sex hormones like estrogen and the like.
- composition comprising an extract of combined pollen and pistils combined with a pollen grain extract, Royal Jelly and Vitamin E has been sold by Natumin Pharma AB, Kungsangsvagen 27, 561 56 Huskvarna, Sweden, for the treatment of Pre- Menstrual Syndrome (PMS).
- PMS Pre- Menstrual Syndrome
- the present inventors now have found that the administration of the present active composition, previously known only as a remedy to alleviate disorders related to PMS, provides a surprising and unexpected relief of disorders obstructing the normal life of women in the peri-and post-menopause without negative adverse effects.
- the present inventors thus found an unexpected beneficial effect on disorders in relation to normal hormone variations in women of peri- and post-menopausal age, obtained by the administering of a composition comprising, as active ingredients, a water- and/or fat-soluble cytosolic extract of pollen and optionally pistils, optionally in combination with Royal Jelly and Vitamin E.
- the invention is based on this discovery.
- the present invention provides a composition
- a composition comprising, as active ingredients, a water- and/ or fat-soluble cytosolic extract of pollen and optionally pistils optionally combined with Royal Jelly and Vitamin E for manufacturing of a medicament for the treatment of disorders in relation to normal hormone variations in women of peri- and post-menopausal age.
- composition of the present invention is effective against such disorders as hot flashes, tendencies of sweating, palpitations, muscle pains, headache, difficulties in passing water, stress incontinence, dysphoria, dry vaginal and mucous membranes, arthralgia, water retention, irritability, and variations in mood.
- the water-and/or fat-soluble cytosolic extract of pollen and optionally pistils preferably comprises an extract of pollen and pistils (PI 82) combined with an extract of pollen grain (GC FEM), as specified herein below. Both types of extract may be purchased from Allergon AB, Valingevagen 309, S-262 92 Angelholm, Sweden, a Pharmacia company.
- the pollens and pistils used for manufacturing of PI82 and GC FEM extracts are selected and harvested primarily from plants belonging to the grass family (Poaceae). During processing, treatment is performed on the pollen to open and remove the outer cell wall thereof as well as to minimize the risk of allergic pollen reactions.
- PI 82 is a cytosolic pollen-pistil extract rich in superoxide dismutase (SOD) mimics.
- SOD superoxide dismutase
- the source of PI 82 is freshly harvested pollen grains and pistils. The pollen and pistils are allowed to react under very specific conditions. In the reaction, the process of fertilization is initiated between pollen and pistils, and the extract comprises the product thereof. Substances obtained in this reaction are SOD mimics, flavo- noids, tannins and polyphenols.
- SOD superoxide dismutase activity
- PI 82 protects the body from the negative influence of free radicals. Furthermore, PI 82 improves the red cell function, thus improving oxygen perfusion to different tissues.
- GC FEM is a water-soluble cytosolic extract from pollen.
- the cytoplasm content of the pollen contains, in addition to the above-mentioned substances, a high amount of carbohydrates and protein. Furthermore, carotenoids and traces of estrogen substances are found.
- GC FEM contains natural biofiavonoids, vitamins, enzymes and trace elements.
- Royal Jelly is a product of the processing of various plant materials within the salivary glands of the worker honeybees. It is rich in pantothenic acid (also called Vitamin Be;), further vitamins and sterols. It is preferably included in the composition in lyophilized form, preferably concentrated by drying to a ratio of at least 1:3. Royal Jelly may be purchased from AB Montoil, Box 24150, S-104 51 Swiss, Sweden. As a source of Vitamin E, use is preferably made of Dry Vitamin E 50%, Type SD, from F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland. Preferably dl-alpha- tocopherol is used, but other forms might also be valuable.
- common drug processing compounds may be included, such as diluents, glidants, lubricants, disintegrants, flavoring and coloring agents well known to the man skilled in the art of pharmaceutical sciences.
- the active ingredients may be included in formulations of any form, such as tablets, powders, granules, and tinctures. They also may be included in foodstuff of different origin, e.g. as functional food. Administration to the woman in need thereof may take place several times a day, such as 1-8 times daily, 1-6 times daily or 1-4 times daily.
- a daily dosage may contain from 60 to 960 mg of PI 82; from 18 to 288 mg of GC FEM; and optionally from 2 to 48 mg of Royal Jelly. Vitamin E might be included in an amount of from 5 to 80 mg.
- a daily dosage may contain from 60 to 480 mg of PI 82; from 20 to 140 mg of GC FEM; optionally from 2 to 30 mg of Royal Jelly; and optionally from 5 to 60 mg/day Vitamin E.
- a daily dosage may contain from 60 to 360 mg of PI 82, 20 to 80 mg of GC FEM, and optionally from 2 to 15 mg of Royal Jelly and optionally from 10 to 40 mg of Vitamin E.
- a daily dosage may contain 240 mg PI 82, 72 mg of GC FEM and optionally 12 mg of Royal Jelly and optionally 20 mg of Vitamin E.
- Vitamin E refers to d-alpha-tocopherol, unless no statement to the contrary is made.
- the remedy comprising the active ingredients should be administered to the woman in need thereof daily during at least one month, preferably at least two months.
- the mode of action is with present scientific knowledge not known. As the product contains three different natural constituents, each with a theoretically contributing effect, the combination of these may be a reason for the observed effect.
- the constituents PI 82 and GC FEM contain SOD mimics such as fiavonoids, tannins and polyphenols. These SOD mimics have an effect on free radical formation, which may be a factor involved in redistribution of fluids, including edema, seen under stress situation. An improved oxygen perfusion may also be a contributing effect.
- Vitamin E is added to the composition as an active ingredient or as an antioxidant and stabilizer.
- the treatment did not affect pulse, or systolic or diastolic blood pressure.
- the investigated disorders all relating to variations in the normal sex hormone pattern of women in the peri-and post-menopause, were menopausal hot flashes, tendencies of sweating, palpitations, sleep disorders, vertigo, muscle pains, headache, difficulties in passing water (pollaMuria), stress incontinence, dysphoria, dry- vaginal and mucous membranes, arthralgia, water retention (edema), irritability, and variations in mood. Evaluation of the disorder was performed by use of a 10-cm VAS (visual analogous scale). Low values express favourable results. All statistical calculations are Wil- coxon test for matched pairs, if not otherwise stated. The results, illustrating the impact of active compositions on different menopausal disorders, are compiled in Table 1.
- Hot flushes significant (p ⁇ 0.02) after two months. Sweating tendencies: significant (p ⁇ 0.05) after two months. Palpitations: more than 50% reduction (borderline significant). Muscle pains: significant (p ⁇ 0.02) after one month and borderline after two months.
- Headache highly significant (p ⁇ 0.01) after one and two months. Stress incontinence and/ or pollakiuria: reduction of about 60%, borderline significant.
- Dysphoria significant after one and two months (p ⁇ 0.05 and p ⁇ 0.02). Dry vaginal or mucous membranes and/or pain during intercourse: significant after one and two months (p ⁇ 0.01 and p ⁇ 0.01) >50% reduction. Joint pain: significant after two months (p ⁇ 0.02)
- Irritability reduced by 50% (p ⁇ 0.01 and p ⁇ 0.05). Sleep disturbances show a tendency of effect but is not significant. Mood swings: borderline significant after two months. Oversensitivity: significantly better after one and two months (p ⁇ 0.05 and p ⁇ 0.02).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Insects & Arthropods (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002522917A JP4896354B2 (en) | 2000-09-01 | 2001-08-31 | Composition comprising pollen extract for the treatment of hormone related diseases |
DE60107443T DE60107443D1 (en) | 2000-09-01 | 2001-08-31 | USE OF A POLLEN EXTRACT-CONTAINING COMPOUND FOR TREATING HORMONE-ASSOCIATED DISEASES |
EP01961557A EP1313495B1 (en) | 2000-09-01 | 2001-08-31 | Use of a composition comprising an extract of pollen for the treatment of hormonally-related disorders |
CA002424146A CA2424146A1 (en) | 2000-09-01 | 2001-08-31 | Use of a composition comprising an extract of pollen for the treatment of hormonally-related disorders |
PL360652A PL202468B1 (en) | 2000-09-01 | 2001-08-31 | Use of a composition comprising an extract of pollen for the treatment of hormonally-related disorders |
AT01961557T ATE283060T1 (en) | 2000-09-01 | 2001-08-31 | USE OF A COMPOUND CONTAINING POLLEN EXTRACT FOR THE TREATMENT OF HORMONE-ASSOCIATED DISEASES |
AU2001282816A AU2001282816A1 (en) | 2000-09-01 | 2001-08-31 | Use of a composition comprising an extract of pollen for the treatment of hormonally-related disorders |
NO20030988A NO330691B1 (en) | 2000-09-01 | 2003-03-03 | Use of a composition comprising a pollen extract for the treatment of hormone-related disorders associated with menopause in women as well as a composition comprising such an extract. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0003092A SE0003092D0 (en) | 2000-09-01 | 2000-09-01 | New Use |
SE0003092-4 | 2000-09-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002017944A1 true WO2002017944A1 (en) | 2002-03-07 |
Family
ID=20280860
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE2001/001848 WO2002017941A1 (en) | 2000-09-01 | 2001-08-31 | Use of a composition comprising an extract of pollen for the treatment of edema |
PCT/SE2001/001850 WO2002017943A1 (en) | 2000-09-01 | 2001-08-31 | Use of a composition comprising an extract of pollen for the treatment of disease-related weight gain |
PCT/SE2001/001847 WO2002017940A1 (en) | 2000-09-01 | 2001-08-31 | Use of a composition comprising an extract of pollen for the treatment of dysphoria |
PCT/SE2001/001849 WO2002017942A1 (en) | 2000-09-01 | 2001-08-31 | Use of a composition comprising an extract of pollen for the treatment of irritability |
PCT/SE2001/001851 WO2002017944A1 (en) | 2000-09-01 | 2001-08-31 | Use of a composition comprising an extract of pollen for the treatment of hormonally-related disorders |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE2001/001848 WO2002017941A1 (en) | 2000-09-01 | 2001-08-31 | Use of a composition comprising an extract of pollen for the treatment of edema |
PCT/SE2001/001850 WO2002017943A1 (en) | 2000-09-01 | 2001-08-31 | Use of a composition comprising an extract of pollen for the treatment of disease-related weight gain |
PCT/SE2001/001847 WO2002017940A1 (en) | 2000-09-01 | 2001-08-31 | Use of a composition comprising an extract of pollen for the treatment of dysphoria |
PCT/SE2001/001849 WO2002017942A1 (en) | 2000-09-01 | 2001-08-31 | Use of a composition comprising an extract of pollen for the treatment of irritability |
Country Status (10)
Country | Link |
---|---|
EP (5) | EP1313495B1 (en) |
JP (5) | JP4896354B2 (en) |
AT (5) | ATE286739T1 (en) |
AU (7) | AU8281401A (en) |
CA (5) | CA2424026A1 (en) |
DE (5) | DE60107444T2 (en) |
NO (1) | NO330691B1 (en) |
PL (1) | PL202468B1 (en) |
SE (1) | SE0003092D0 (en) |
WO (5) | WO2002017941A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005139150A (en) * | 2003-11-10 | 2005-06-02 | Api Co Ltd | Estrogenic agent, method for producing the same, prophylactic agent for osteoporosis and food and beverage |
FR3055215A1 (en) * | 2016-08-31 | 2018-03-02 | S.A.M. Serelys Pharma | COMPOSITION COMPRISING POLLEN EXTRACTS AND / OR PISTILS |
EP3335717A1 (en) * | 2016-12-13 | 2018-06-20 | Serelys Pharma S.A.M. | Composition for use in treating symptoms relating to premenstrual syndrome (pms) |
WO2019042934A1 (en) * | 2017-08-28 | 2019-03-07 | Sérélys Pharma S.A.M. | Composition for use of same in the treatment and/or prevention of infertility |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7887851B2 (en) | 2004-06-07 | 2011-02-15 | Kao Corporation | Aromatase activator |
CN104027100A (en) * | 2014-06-12 | 2014-09-10 | 山东中弘信息科技有限公司 | Abnormal blood pressure data processing method based on latest historical values |
KR101533197B1 (en) * | 2014-09-18 | 2015-07-02 | 성균관대학교산학협력단 | Composition comprising butein for preventing or treating edema |
CN106138856A (en) * | 2016-09-30 | 2016-11-23 | 四川易创生物科技有限公司 | A kind of new medicine composition treating intermenstrual bleeding and preparation method |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5569459A (en) * | 1995-02-15 | 1996-10-29 | Bio-Virus Research Incorporated | Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders |
EP1057483A1 (en) * | 1998-02-23 | 2000-12-06 | Taiyo Kagaku Co., Ltd. | Composition comprising theanine |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2970957B2 (en) * | 1991-05-15 | 1999-11-02 | 株式会社グレイトチレン | Refined pollen nutritional preparation |
ES2081255B1 (en) * | 1994-01-05 | 1996-09-01 | Ind Farma Especial | APPLICATION OF THE RECEPTOR PROTEINS OF AUTOINCOMPATIBILITY (SLSG) OF PLANTS FOR THE TREATMENT OF ALLERGIC DISEASES. |
JPH09278665A (en) * | 1996-04-10 | 1997-10-28 | Api Kk | Pollen extract soft capsule and its production |
-
2000
- 2000-09-01 SE SE0003092A patent/SE0003092D0/en unknown
-
2001
- 2001-08-31 AU AU8281401A patent/AU8281401A/en active Pending
- 2001-08-31 JP JP2002522917A patent/JP4896354B2/en not_active Expired - Lifetime
- 2001-08-31 DE DE60107444T patent/DE60107444T2/en not_active Expired - Lifetime
- 2001-08-31 AU AU2001282814A patent/AU2001282814B2/en not_active Expired
- 2001-08-31 AU AU8458101A patent/AU8458101A/en active Pending
- 2001-08-31 CA CA002424026A patent/CA2424026A1/en not_active Abandoned
- 2001-08-31 WO PCT/SE2001/001848 patent/WO2002017941A1/en active IP Right Grant
- 2001-08-31 AU AU2001284581A patent/AU2001284581B2/en not_active Ceased
- 2001-08-31 CA CA002424011A patent/CA2424011A1/en not_active Abandoned
- 2001-08-31 AT AT01961556T patent/ATE286739T1/en not_active IP Right Cessation
- 2001-08-31 DE DE60108402T patent/DE60108402D1/en not_active Expired - Lifetime
- 2001-08-31 DE DE60107443T patent/DE60107443D1/en not_active Expired - Lifetime
- 2001-08-31 JP JP2002522913A patent/JP2004507506A/en active Pending
- 2001-08-31 WO PCT/SE2001/001850 patent/WO2002017943A1/en active IP Right Grant
- 2001-08-31 EP EP01961557A patent/EP1313495B1/en not_active Expired - Lifetime
- 2001-08-31 PL PL360652A patent/PL202468B1/en unknown
- 2001-08-31 AT AT01961557T patent/ATE283060T1/en not_active IP Right Cessation
- 2001-08-31 WO PCT/SE2001/001847 patent/WO2002017940A1/en active IP Right Grant
- 2001-08-31 CA CA2420906A patent/CA2420906C/en not_active Expired - Lifetime
- 2001-08-31 AU AU2001282816A patent/AU2001282816A1/en not_active Abandoned
- 2001-08-31 AU AU2001282815A patent/AU2001282815A1/en not_active Abandoned
- 2001-08-31 JP JP2002522914A patent/JP2004507507A/en active Pending
- 2001-08-31 WO PCT/SE2001/001849 patent/WO2002017942A1/en active IP Right Grant
- 2001-08-31 AT AT01963652T patent/ATE283061T1/en not_active IP Right Cessation
- 2001-08-31 DE DE60107442T patent/DE60107442D1/en not_active Expired - Lifetime
- 2001-08-31 DE DE60107441T patent/DE60107441D1/en not_active Expired - Lifetime
- 2001-08-31 EP EP01961556A patent/EP1313494B1/en not_active Expired - Lifetime
- 2001-08-31 JP JP2002522915A patent/JP2004507508A/en active Pending
- 2001-08-31 CA CA2420823A patent/CA2420823C/en not_active Expired - Lifetime
- 2001-08-31 JP JP2002522916A patent/JP2004507509A/en active Pending
- 2001-08-31 EP EP01963652A patent/EP1313496B1/en not_active Expired - Lifetime
- 2001-08-31 AT AT01961555T patent/ATE283059T1/en not_active IP Right Cessation
- 2001-08-31 AT AT01961554T patent/ATE283058T1/en not_active IP Right Cessation
- 2001-08-31 EP EP01961555A patent/EP1313493B1/en not_active Expired - Lifetime
- 2001-08-31 CA CA002424146A patent/CA2424146A1/en not_active Abandoned
- 2001-08-31 AU AU2001282813A patent/AU2001282813A1/en not_active Abandoned
- 2001-08-31 EP EP01961554A patent/EP1313492B1/en not_active Expired - Lifetime
- 2001-08-31 WO PCT/SE2001/001851 patent/WO2002017944A1/en active IP Right Grant
-
2003
- 2003-03-03 NO NO20030988A patent/NO330691B1/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5569459A (en) * | 1995-02-15 | 1996-10-29 | Bio-Virus Research Incorporated | Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders |
EP1057483A1 (en) * | 1998-02-23 | 2000-12-06 | Taiyo Kagaku Co., Ltd. | Composition comprising theanine |
Non-Patent Citations (2)
Title |
---|
"Femal - Nature help for PMS", XP002906801, Retrieved from the Internet <URL:http://www.sisuhealth.com/products/Femal.html> [retrieved on 20010419] * |
"Menopause treatment options", XP002906802, Retrieved from the Internet <URL:http://www.menopause.org/mgremedies.htm> [retrieved on 20010420] * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005139150A (en) * | 2003-11-10 | 2005-06-02 | Api Co Ltd | Estrogenic agent, method for producing the same, prophylactic agent for osteoporosis and food and beverage |
FR3055215A1 (en) * | 2016-08-31 | 2018-03-02 | S.A.M. Serelys Pharma | COMPOSITION COMPRISING POLLEN EXTRACTS AND / OR PISTILS |
WO2018041790A1 (en) | 2016-08-31 | 2018-03-08 | Sérélys Pharma S.A.M. | Composition comprising pollen and/or pistil extracts, preparation process and associated uses |
US12029775B2 (en) | 2016-08-31 | 2024-07-09 | Axeen Pharma S.A.R.L. | Composition comprising pollen and/or pistil extracts, preparation process and associated uses |
EP3335717A1 (en) * | 2016-12-13 | 2018-06-20 | Serelys Pharma S.A.M. | Composition for use in treating symptoms relating to premenstrual syndrome (pms) |
WO2018108879A1 (en) * | 2016-12-13 | 2018-06-21 | Sérélys Pharma S.A.M. | Composition for use in treating dysphoria, depression and/or mood swings relating to premenstrual syndrome (pms) |
WO2019042934A1 (en) * | 2017-08-28 | 2019-03-07 | Sérélys Pharma S.A.M. | Composition for use of same in the treatment and/or prevention of infertility |
US11253563B2 (en) | 2017-08-28 | 2022-02-22 | Serelys Pharma S.A.M. | Composition for use in the treatment and/or prevention of infertility |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190008907A1 (en) | Compositions for management of wounds, skin diseases, dehydration, chronic diseases, and respiratory diseases | |
EP1313495B1 (en) | Use of a composition comprising an extract of pollen for the treatment of hormonally-related disorders | |
Rohdewald | Update on the clinical pharmacology of Pycnogenol (R) | |
AU2001284581A1 (en) | Use of a composition comprising an extract of pollen for the treatment of edema | |
AU2001282814A1 (en) | Use of a composition comprising an extract of pollen for the treatment of irritability | |
US6569471B2 (en) | Method for the treatment of symptoms related to normal hormonal variations in women | |
US6669967B2 (en) | Method for the treatment of symptoms related to normal hormonal variations in women | |
RU2736997C1 (en) | Agent for treating hot flashes and recuperating menstrual cycle during perimenopause and method of using it | |
EP1581195B1 (en) | Film coated tablet comprising an extract of red vine leaves | |
NO330158B1 (en) | Use of xanthophylls | |
KR100462173B1 (en) | A composition for prevention and treatment of urinary incontinence | |
CN116785384A (en) | Traditional Chinese medicine composition for protecting gastric mucosa and preparation method thereof | |
ZA200505059B (en) | Film coated tablet comprising an extract of red vine leaves |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001961557 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001282816 Country of ref document: AU Ref document number: 2424146 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002522917 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001961557 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001961557 Country of ref document: EP |